Mark Brister, Chief Technology Officer at OBALON THERAPEUTICS INC (OBLN), bought 5,000 shares at $4.00 ($20K) on 2019-08-06, disclosed to the SEC on 2019-08-08.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.